<DOC>
	<DOCNO>NCT01283217</DOCNO>
	<brief_summary>Docetaxel first drug show survival benefit add CF regimen , toxic . Docetaxel also synergistic anti-cancer effect S-1 , phase I/II study . The use docetaxel plus S-1 combination first-line chemotherapy advance gastric cancer achieve response rate 46~56 % median survival time 14.0~14.3 month . Based upon background , aim study detect significant increase 3 year DFS disease test group ( DS ) relative Control group ( SP ) .</brief_summary>
	<brief_title>Docetaxel S1 ( DS ) Versus S1 Cisplatin ( SP ) Curatively Resected Stage IIIB/IV Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically proven , Stage IIIb/ IIIc curatively resect gastric carcinoma ECOG performance status 01 Curatively resect advanced gastric cancer patient stage IIIb/IIIc D2 lymph node dissection R0 surgery Signed informed consent Subjects document distant metastasis . Malabsorption syndrome disease significantly affect gastrointestinal function Patients uncontrolled systemic illness , e.g . infection , poorly control HTN History malignancy . Subjects diseasefree 5 year subject successfully treat situ carcinoma eligible . Subjects preoperative/adjuvant cancer treatment , chemotherapy , immunotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>